Please use this identifier to cite or link to this item:
|Title:||Inherited breast cancer predisposition in Asians: Multigene panel testing outcomes from Singapore||Authors:||Wong, E.S.Y
|Issue Date:||2016||Citation:||Wong, E.S.Y, Shekar, S, Met-Domestici, M, Chan, C, Sze, M, Yap, Y.S, Rozen, S.G, Tan, M.-H, Ang, P, Ngeow, J, Lee, A.S.G (2016). Inherited breast cancer predisposition in Asians: Multigene panel testing outcomes from Singapore. npj Genomic Medicine 1 : 15003. ScholarBank@NUS Repository. https://doi.org/10.1038/npjgenmed.2015.3||Abstract:||Genetic testing for germline mutations in breast cancer predisposition genes can potentially identify individuals at a high risk of developing breast and/or ovarian cancer. There is a paucity of such mutational information for Asians. Panel testing of 25 cancer susceptibility genes and BRCA1/2 deletion/duplication analysis was performed for 220 Asian breast cancer patients or their family members referred for genetics risk assessment. All 220 participants had at least one high-risk feature: having a family history of breast and/or ovarian cancer in first-And/or second-degree relatives; having breast and ovarian cancer in the same individual or bilateral breast cancer; having early-onset breast cancer or ovarian cancer (40 years of age). We identified 67 pathogenic variants in 66 (30.0%) patients. Of these, 19 (28.3%) occurred in BRCA1, 16 (23.9%) in BRCA2, 7 (10.4%) in PALB2, 6 (9.0%) in TP53, 2 (3.0%) in PTEN, 2 (3.0%) in CDH1 and 15 (22.4%) in other predisposition genes. Notably, 47.8% of pathogenic variants were in non-BRCA1/2 genes. Of the 66 patients with pathogenic mutations, 63.6% (42/66) were under the age of 40 years. Family history of breast and/or ovarian cancer is enriched in patients with BRCA1/2 pathogenic variants but less predictive for non-BRCA1/2 related pathogenic variations. We detected a median of three variants of unknown significance (VUS) per gene (range 0-21). Custom gene panel testing is feasible and useful for the detection of pathogenic mutations and should be done in the setting of a formal clinical cancer genetics service given the rate of VUS. © 2016 Center of Excellence in Genomic Medicine Research/Macmillan Publishers Limited.||Source Title:||npj Genomic Medicine||URI:||https://scholarbank.nus.edu.sg/handle/10635/174034||ISSN:||20567944||DOI:||10.1038/npjgenmed.2015.3|
|Appears in Collections:||Elements|
Show full item record
Files in This Item:
|10_1038_npjgenmed_2015_3.pdf||524.48 kB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.